82654-75-9

Basic information

• Product Name: 1,4-dihydroxy-5,8-bis((2-(2-hydroxyethoxy)ethyl)amino)-9,10-anthracenedione
• Synonyms: 1,4-dihydroxy-5,8-bis((2-(2-hydroxyethoxy)ethyl)amino)-9,10-anthracenedione
• CAS NO: 82654-75-9
• Molecular Formula: C22H26N2O8
• Molecular Weight: 0
• Mol File: 82654-75-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 783.6°C at 760 mmHg
• Flash Point: 427.7°C
• Appearance: /
• Density: 1.48g/cm³
• Vapor Pressure: 7.35E-26mmHg at 25°C
• Refractive Index: 1.695
• CAS DataBase Reference: 1,4-dihydroxy-5,8-bis((2-(2-hydroxyethoxy)ethyl)amino)-9,10-anthracenedione(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-dihydroxy-5,8-bis((2-(2-hydroxyethoxy)ethyl)amino)-9,10-anthracenedione(82654-75-9)
• EPA Substance Registry System: 1,4-dihydroxy-5,8-bis((2-(2-hydroxyethoxy)ethyl)amino)-9,10-anthracenedione(82654-75-9)

Safety Data

• Hazardous Substances Data: 82654-75-9(Hazardous Substances Data)

Usage

Explanation

The compound's full chemical name, which describes its structure and composition.

Explanation

A more commonly used name for the compound, making it easier to refer to in medical and pharmaceutical contexts.

Explanation

The compound belongs to a specific class of antibiotics, which are characterized by their structure and mechanism of action.

Explanation

The main application of this compound is in the treatment of certain types of cancer.

Explanation

The compound works by stopping the growth and spread of cancer cells within the body.

Explanation

Idarubicin is particularly effective in treating leukemia but can also be used for other types of cancer.

Explanation

The compound is administered through an IV injection, allowing it to enter the bloodstream directly.

Explanation

Due to its potential side effects and toxic nature, the compound must be administered and monitored under strict medical supervision.

Explanation

The compound can cause side effects, which must be carefully managed by healthcare professionals.

Explanation

The compound remains a subject of ongoing research to better understand its potential benefits and to determine the most effective ways to use it in cancer treatment.

Class

Anthracycline antibiotics

Primary Use

Cancer treatment

Mechanism of Action

Inhibits growth and spread of cancer cells

Cancer Types

Leukemia and other forms of cancer

Administration

Intravenous injection

Supervision

Strict medical supervision

Side Effects

Potential adverse effects

Ongoing Research

Potential benefits and optimal usage

InChI:InChI=1/C22H26N2O8/c25-7-11-31-9-5-23-13-1-2-14(24-6-10-32-12-8-26)18-17(13)21(29)19-15(27)3-4-16(28)20(19)22(18)30/h1-4,23-28H,5-12H2

Upstream product

• 81-59-4 1,4,5,8-tetrahydroxy-2,3-dihydro-9,10-anthracenedione 
• 929-06-6 2-(2-Aminoethoxy)ethanol 

Relevant articles and documents

Structure-activity relationship study of anthraquinones: 1,4-dihydroxy-5,8-bis[[2-(2-hydroxyethoxy)ethyl]amino]-9,10-anthracenedione, an analog of an established antineoplastic agent

-